Time‐dependent benefits of pre‐treatment with new oral P2Y₁₂‐inhibitors in patients addressed to primary PCI for acute ST‐elevation myocardial infarction

Abstract

Objectives The aim of this observational study was to determine the benefits of the novel, orally delivered P2Y12‐inhibitors (Is) in terms of angiographic endpoints and in relation to the time of the loading dose (LD) administration. Background The goal of ST‐elevation myocardial infarction (STEMI) treatment is timely reperfusion. The P2Y12‐Is prasugrel and ticagrelor have improved the angiographic outcome of primary percutaneous coronary intervention (pPCI) and patients' prognosis. However, their onset of action is impaired in STEMI and delayed by their oral administration. Methods The 328 eligible patients with STEMI consecutively referred for pPCI were divided into three groups depending on the interval of “P2Y12‐I LD administration‐to‐balloon time”: Group 2 included patients that received P2Y12‐I LD at least 60 min prior to pPCI, Group 1 within 60 min prior to pPCI, and Group 0 at the moment of pPCI. Angiographic, clinical, and biochemical parameters were evaluated. Pre‐ and post‐pPCI TIMI flow grade (TFG) and ST resolution (STR) were used as outcome measures to determine efficacy and optimal timing of pretreatment. Results Pre‐pPCI TFG improved with increasing P2Y12‐I LD administration‐to‐balloon time; pre‐PCI TFG 0/1 was 74.5% in Group 0, 65.5% in Group 1 and 54.9% in Group 2 (P < 0.002). Post‐pPCI TFG 3 results also differed significantly between the three groups: 85.2% in Group 0, 88.1% in Group 1, 97.6% in Group 2 (P < 0.013). ST resolution rates were also positively associated with longer pretreatment intervals. Conclusions This observational study suggests that the angiographic benefit of P2Y12‐I administration is time‐dependent: longer pretreatment improves coronary reperfusion in terms of pre‐ and post‐pPCI TFG and STR.

The calculus of preloading antiplatelet agents in ST‐elevation myocardial infarction: Does it make a difference?

“…In this issue of Catheterization and Cardiovascular Interventions , Pepe et al add to the limited evidence base with a unique analysis of 328 eligible consecutive STEMI patients referred to their center for primary PCI. Unlike other studies where the delays to PCI are minimal, this study included patients that were transferred from other facilities, allowing for analysis of the time dependence of P2Y12 inhibition.…”

Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry

“…In fact, limitations of Clopidogrel, Prasugrel, and Ticagrelor (all oral P2Y 12 -I) are the slow onset and offset of action and the impossibility to be administrated or to be fully effective in patients with orotracheal intubation, vomit, and impaired intestinal absorption 5 . In detail, the extremely short time gap between first medical contact (FMC) and primary PCI jeopardizes the effectiveness of the administration of oral P2Y 12 -I in ST elevation myocardial infarction (STEMI) patients, while in the setting of non-ST elevation (NSTE) ACS the administration of an oral P2Y 12 -I prior to coronary angiography (pretreatment strategy) is discouraged by the current ESC guidelines 1 , 6 .…”

Anti-Inflammatory Therapy for Acute Coronary Syndromes: Is It Time for a Shift in the Treatment Paradigm?

“…Effectiveness of reperfusion strategies as well as of supportive therapies, such as P2Y12 inhibitors, has been proved, over the years, to be strictly time-dependent. 8 As a consequence, the ideal timing of SP16 must be a further crucial object of upcoming investigations.…”